ArticleACS omega2023
Improved Machine Learning-Based Model for the Classification of Off-Targets in the CRISPR/Cpf1 System.
Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Conformational changes induced by K949A mutation in the CRISPR-Cas12a complex drives an effective target-binding mechanism.Current research in structural biology · 2025Article
- An efficient hairy root system for validation of CRISPR/Cas system activities in cotton.Functional & integrative genomics · 2025Article
- Unlocking the potential of CRISPR tools and databases for precision genome editing.Frontiers in plant science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted nucleases are widely used for altering the specific location of the genome with precision. The endonucleases facilitate efficient genome editing via designing a guide RNA (gRNA) consisting of a 20-nucleotide target sequence. gRNA preferably binds to the target location, but the on- and off-target activities of gRNAs vary widely. The off-target activity due to mismatch tolerance in the CRISPR-Cas system is a major factor inhibiting its clinical applications. Ensuring on-target efficiency and minimizing off-targets for a target sequence are the major objectives of this study. A pipeline has been designed to predict potential off-target sites in the human genome for a target sequence, and a multilayer perceptron (MLP) has been used to predict the cleavage efficiency of the potential off-target sites. An MLP-based classifier was trained with sequence- and base-dependent binding energy-associated features for AsCpf1 and LbCpf1 to predict the target efficiencies. Positional preferences of nucleotides, distribution of mismatches, and classification-dependent feature importance between high-activity and low-activity off-targets were also studied. Positional preference of nucleotides revealed that thymine is highly disfavored at positions adjacent to Protospacer Adjacent Motif (PAM), whereas guanine is favored in high-activity off-targets. Mismatch distribution analysis revealed that mismatches were more prominent in the trunk region (16, 17, 18 nucleotides from PAM sequence), and the promiscuous region and transition type mismatch were more preferred at 16, 17, and 18 nucleotides positions. The distribution of mismatches was a distinctive feature between high-activity and low-activity off-targets. Thermodynamics-associated features such as low to moderate melting temperature of the nonseed region and base-dependent PAM binding energy were predicted as best predictors by the multilayer perceptron for high-activity off-targets. GC content, some types of dinucleotide frequencies, number of bulges, and mismatches in the seed and trunk regions were other characteristic features between high-activity and low-activity off-targets for both LbCpf1 and AsCpf1.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.